Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy
Multiple myeloma science from EHA 2019
CAR T-cell therapy for treating acute leukaemia
Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma
Combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia
The changing landscape of AML
Chemoimmunotherapy or BTK inhibition for patients with CLL
CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL
CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL
CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML